Could six months of targeted therapy be enough for some breast cancer patients?

NCT ID NCT04928261

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether patients with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and HER2-targeted therapy can safely receive only 6 months of further HER2 treatment instead of the standard 12 months. The goal is to reduce heart side effects and treatment burden while maintaining effectiveness. The trial will enroll 52 participants across multiple Canadian centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab (Herceptin)
What this could lead to
If successful, this could show that a shorter course of HER2-targeted therapy is safe and effective for patients who have a complete response to initial treatment, reducing heart risks and treatment burden.
What could go wrong
This is a small, single-arm study with only 52 participants, so results may not apply broadly. Shorter therapy might increase the risk of cancer recurrence, and heart side effects remain a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, K1H8M2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.